Horizon Therapeutics PLC
NASDAQ:HZNP
Intrinsic Value
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. [ Read More ]
The intrinsic value of one
HZNP
stock under the Base Case scenario is
91.92
USD.
Compared to the current market price of 116.3 USD,
Horizon Therapeutics PLC
is
Overvalued by 21%.
Horizon Therapeutics PLC's market capitalization is 26.6B USD.
HZNP stock price is 116.3 USD.
HZNP stock (91.92 USD) is 21% less than its price (116.3 USD).
HZNP stock (105.31 USD) is 9% less than its price (116.3 USD). Open Relative Valuation
HZNP has upside potential of 0% compared to the average analyst price target.
Open Wall St Estimates
HZNP's ROE (Return on Equity) has decreased in the last 3 years from 9% to 9%.
HZNP's ROIC (Return on Invested Capital) has increased in the last 3 years from 7% to 8%.
HZNP's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
HZNP's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
HZNP's Revenue has dropped by 4% over the past 12 months.
HZNP's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
HZNP has positive Operating Income for the last twelve months.
HZNP has positive three-year average ROE (Return on Equity): 15%. The company is efficient at transforming stockholders' equity into net income.
HZNP has positive Net Debt. This means that the company has more debt (3B USD) than cash and short-term investments (2B USD).
HZNP has positive Net Income for the last twelve months.
HZNP's Revenue has been growing by an exceptional 34% per year for the last 3 years.
HZNP's long-term assets (9B USD) exceed its long-term liabilties (4B USD).
HZNP's D/E (Debt to Equity) is very low and is equal to 0.48.
HZNP has positive Gross Profit for the last twelve months.
HZNP has positive Free Cash Flow for the last twelve months.
HZNP has negative three-year average ROIC (Return on Invested Capital): -19%. The company is not efficient at using invested capital to generate operating income.
HZNP's short-term assets (4B USD) exceed its short-term liabilties (918m USD).
HZNP's Altman Z-Score is very high and is equal to 4.32.
HZNP generates enough operating income (568m USD) to cover interest payments on its debt (139m USD).
Valuation Backtest
Horizon Therapeutics PLC
Run backtest to discover the historical profit from buying and selling
HZNP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Horizon Therapeutics PLC
Balance Sheet Decomposition
Horizon Therapeutics PLC
| Current Assets | 3.9B |
| Cash & Short-Term Investments | 2.5B |
| Receivables | 717.4m |
| Other Current Assets | 739.9m |
| Non-Current Assets | 5.4B |
| PP&E | 504.2m |
| Intangibles | 4.3B |
| Other Non-Current Assets | 565.4m |
| Current Liabilities | 917.7m |
| Accounts Payable | 85.5m |
| Accrued Liabilities | 816.1m |
| Other Current Liabilities | 16m |
| Non-Current Liabilities | 3.1B |
| Long-Term Debt | 2.5B |
| Other Non-Current Liabilities | 528.6m |
Earnings Waterfall
Horizon Therapeutics PLC
|
Revenue
|
3.6B
USD
|
|
Cost of Revenue
|
-903.4m
USD
|
|
Gross Profit
|
2.7B
USD
|
|
Operating Expenses
|
-2.2B
USD
|
|
Operating Income
|
567.6m
USD
|
|
Other Expenses
|
-129.6m
USD
|
|
Net Income
|
438m
USD
|
Free Cash Flow Analysis
Horizon Therapeutics PLC
HZNP Profitability Score
Profitability Due Diligence
Horizon Therapeutics PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Horizon Therapeutics PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
HZNP Solvency Score
Solvency Due Diligence
Horizon Therapeutics PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Horizon Therapeutics PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HZNP Price Targets Summary
Horizon Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
HZNP
is 116.5 USD
.
Ownership
HZNP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
HZNP Price
Horizon Therapeutics PLC
| Average Annual Return | 63.04% |
| Standard Deviation of Annual Returns | 31.73% |
| Max Drawdown | -51% |
| Market Capitalization | 26.6B USD |
| Shares Outstanding | 228 995 008 |
| Percentage of Shares Shorted | 3.12% |
HZNP News
Last Important Events
Horizon Therapeutics PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Horizon Therapeutics PLC
Company Profile
Horizon Therapeutics PLC
Country
Industry
Market Cap
Dividend Yield
Description
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 1,890 full-time employees. The company went IPO on 2010-08-11. The firm's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The firm has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The firm's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.
Contact
IPO
Employees
Officers
The intrinsic value of one
HZNP
stock under the Base Case scenario is
91.92
USD.
Compared to the current market price of 116.3 USD,
Horizon Therapeutics PLC
is
Overvalued by 21%.
You don't have any saved screeners yet
